Olanzapina, aripiprazol, amisulpryd i kwetiapina – powody zastosowania w terapii schizofrenii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2019
Słowa kluczowe:
schizofrenia, aripiprazol, amisulpryd, kwetiapina, olanzapina
##plugins.themes.bootstrap3.article.main##
Abstrakt
Celem artykułu jest przedstawienie podstawowych cech amisulprydu, aripiprazolu, kwetiapiny i olanzapiny – 4 często stosowanych leków przeciwpsychotycznych. Wskazano najważniejsze różnice w profilu działania klinicznego i profilu tolerancji. Znajomość tych cech pozwala na dokonywanie bardziej zindywidualizowanych wyborów w leczeniu chorych na schizofrenię.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szafrański, T. (2019). Olanzapina, aripiprazol, amisulpryd i kwetiapina – powody zastosowania w terapii schizofrenii. Medycyna Faktów , 12(1(42), 75-79. https://doi.org/10.24292/01.MF.0119.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Azekawa T., Ohashi S. Itami A.: Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr. Dis. Treat. 2011; 7: 691-695.
2. Citrome L.: Interpreting and Applying the CATIE Results. Psychiatry (Edgmont) 2007; 4(10): 23-29.
3. Correll C.U.: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25(supl. 2): S12-S21.
4. Galling B., Roldan A., Rietschel L. et al.: Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin. Drug Saf. 2016; 15(5): 591-612.
5. Hendrick V., Dasher R., Gitlin M., Parsi M.: Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin. Ann. Clin. Psychiatry 2017; 29(2): 120-124.
6. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
7. Kahn R.S., Winter van Rossum I., Leucht S. et al.: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5(10): 797-807.
8. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569.
9. Komossa K., Rummel-Kluge C., Hunger H. et al.: Amisulpride versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst. Rev. 2010; 1: CD006624.
10. Krause M., Zhu Y., Huhn M. et al.: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2018; 268(7): 625-639. DOI: 10.1007/s00406-018-0869-3.
11. Leucht S., Arbter D., Engel R.R. et al.: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009; 14(4): 429-447.
12. Leucht S., Cipriani A., Spineli L. et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-962.
13. Leucht S., Tardy M., Komossa K. et al.: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063-2071.
14. Mortimer A.M.: Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009; 5: 267-277.
15. Muneer A.: Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin. Psychopharmacol. Neurosci. 2015; 13(1): 25-35.
16. van Rooijen G., Vermeulen J.M., Ruhé H.G., de Haan L.: Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2017: 1-10.
17. Samara M.T., Dold M., Gianatsi M. et al.: Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73(3): 199-210
18. Solmi M., Murru A., Pacchiarotti I. et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther. Clin. Risk Manag. 2017; 13: 757-777.
19. Temmingh H., Stein D.J.: Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 2015; 29(10): 819-832.
20. Topolov M.K., Getova D.P.: Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia Medica 2016; 58(1): 12-18.
21. Vancampfort D., Stubbs B., Mitchell A.J. et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14(3): 339-347.
22. Zhu Y., Krause M., Huhn M. et al.: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4(9): 694-705.
2. Citrome L.: Interpreting and Applying the CATIE Results. Psychiatry (Edgmont) 2007; 4(10): 23-29.
3. Correll C.U.: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25(supl. 2): S12-S21.
4. Galling B., Roldan A., Rietschel L. et al.: Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin. Drug Saf. 2016; 15(5): 591-612.
5. Hendrick V., Dasher R., Gitlin M., Parsi M.: Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin. Ann. Clin. Psychiatry 2017; 29(2): 120-124.
6. Kahn R.S., Fleischhacker W.W., Boter H. et al.: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
7. Kahn R.S., Winter van Rossum I., Leucht S. et al.: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5(10): 797-807.
8. Khanna P., Komossa K., Rummel-Kluge C. et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2013; 2: CD006569.
9. Komossa K., Rummel-Kluge C., Hunger H. et al.: Amisulpride versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst. Rev. 2010; 1: CD006624.
10. Krause M., Zhu Y., Huhn M. et al.: Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2018; 268(7): 625-639. DOI: 10.1007/s00406-018-0869-3.
11. Leucht S., Arbter D., Engel R.R. et al.: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009; 14(4): 429-447.
12. Leucht S., Cipriani A., Spineli L. et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951-962.
13. Leucht S., Tardy M., Komossa K. et al.: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063-2071.
14. Mortimer A.M.: Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009; 5: 267-277.
15. Muneer A.: Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin. Psychopharmacol. Neurosci. 2015; 13(1): 25-35.
16. van Rooijen G., Vermeulen J.M., Ruhé H.G., de Haan L.: Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2017: 1-10.
17. Samara M.T., Dold M., Gianatsi M. et al.: Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry 2016; 73(3): 199-210
18. Solmi M., Murru A., Pacchiarotti I. et al.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther. Clin. Risk Manag. 2017; 13: 757-777.
19. Temmingh H., Stein D.J.: Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 2015; 29(10): 819-832.
20. Topolov M.K., Getova D.P.: Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole. Folia Medica 2016; 58(1): 12-18.
21. Vancampfort D., Stubbs B., Mitchell A.J. et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14(3): 339-347.
22. Zhu Y., Krause M., Huhn M. et al.: Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4(9): 694-705.